2014•Patient Preference and AdherenceOpen access
Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
Maria Teresa Petrucci, Paola Finsinger, Fabiana Gentilini, Marta Chisini
Open full text 15 citations
Abstract
The use of novel agents such as thalidomide, lenalidomide, and bortezomib has considerably improved the outcome of multiple myeloma patients. Besides greater biological activity, these drugs unfortunately have also been associated with greater toxicity. To evaluate the positive effect on the quality of life of patients, driven by both the tolerability and antimyeloma activity of bortezomib, we analyzed data that have been published concerning different strategies used to improve its tolerability as once weekly and/or subcutaneous administration.
Open-access reader